Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
恩扎鲁胺
医学
前列腺癌
安慰剂
肿瘤科
内科学
癌症
泌尿科
病理
雄激素受体
替代医学
作者
Arun Azad,Karim Fizazi,Nobuaki Matsubara,Fred Saad,Ugo De Giorgi,Jae Young Joung,Peter C.C. Fong,Robert J. Jones,Stefanie Zschäbitz,Jan Oldenburg,Neal D. Shore,Curtis Dunshee,Joan Carles,André P. Fay,Xun Lin,Liza DeAnnuntis,Nicola Di Santo,Michael A. Zielinski,Neeraj Agarwal
This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in patients with metastatic castration-resistant prostate cancer (mCRPC). In both the all-comers and homologous recombination repair (HRR)-deficient populations, talazoparib plus enzalutamide significantly improved radiographic progression-free survival compared with placebo plus enzalutamide.
爱静静
YJM
VDC
shinysparrow
目目
pcr163
Leon
Yen
时间不移民
小林太郎
幽壑之潜蛟
稳重的雨珍
迟大猫
Magali
阿毛0226
Zn
jyy
我有一头小毛驴
Owen
一夜很静
皖公网安备34019202002308
